FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293073886> ?p ?o ?g. }

• W4293073886 abstract "The aim of this analysis of the XENSOR study was to assess the effect of 2 weight-loss drugs on hepatic serum biomarkers in patients with overweight or obesity and insufficient weight loss (WL) after a lifestyle modification program. A retrospective real-world study (RWS) was conducted comparing the effect of orlistat 120 mg tid and liraglutide (up to 3 mg daily) on liver enzymes in adult patients with BMI &gt; 30 kg/m² (or &gt; 27 kg/m² with at least a weight-related comorbidity) . The primary endpoint was to assess in a multivariate model the differences in ALT and GGT reductions between both drugs over a median follow-up period of 7 months. A secondary endpoint was to study the impact of the amount of WL on both liver enzymes. 400 patients in the group of orlistat (BMI 41.4 kg/m2, ALT 30.1 U/L, GGT 35.7 U/L) , and 100 in the group of liraglutide (BMI 39.7 kg/m2, ALT 27.3 U/L, GGT 29.1 U/L) , were included. WL with liraglutide (−7.7 kg) was significantly greater in comparison with orlistat (−3.3 kg) , p &lt;0.0001. Treatment with both drugs significantly reduced ALT (orlistat −3.8 U/L; liraglutide −5.7 U/L, both p&lt;0.05) . ALT reduction was significantly higher with liraglutide vs. orlistat (adjusted mean difference −3.4 U/L (95% CI −6.5 to −0.2 U/L) . A significant decrease in GGT levels was observed with liraglutide (−5.8 U/L, p&lt;0.0001) , but not with orlistat. Adjusted mean differences in GGT changes between both drugs were not statistically significant. 46% of patients with high ALT levels lowered this enzyme into the normal range at the end of the follow-up, without significant differences between both drugs. When patients were split into 3 groups according to their WL (&lt;5%, 5-10% and &gt;10%) , ALT and GGT reductions were significantly higher in patients with WL&gt;10%. In summary, in this RWS ALT reductions were significantly greater with liraglutide in comparison with orlistat. The effects of both drugs on ALT and GGT were higher in those patients with clinically relevant WL (&gt;10%) . Disclosure J.J.Gorgojo-martinez: Consultant; Mundipharma, Research Support; Novo Nordisk, Speaker's Bureau; Abbott Diabetes, AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Merck Sharp & Dohme Corp., Mundipharma, Novo Nordisk. P.L.Lois chicharro: None. P.J.Ferreira-ocampo: None. S.C.Doejo-marciales: None. S.F.Barra-malig: None. F.Almodovar-ruiz: None." @default.
• W4293073886 created "2022-08-26" @default.
• W4293073886 creator A5020385332 @default.
• W4293073886 creator A5025293866 @default.
• W4293073886 creator A5055924693 @default.
• W4293073886 creator A5073693745 @default.
• W4293073886 creator A5082171339 @default.
• W4293073886 creator A5090069649 @default.
• W4293073886 date "2022-06-01" @default.
• W4293073886 modified "2023-10-06" @default.
• W4293073886 title "1440-P: Effects of Two Weight-Loss Medications, Liraglutide and Orlistat, on Liver Enzymes in Patients with Overweight or Obesity in a Real-World Setting" @default.
• W4293073886 doi "https://doi.org/10.2337/db22-1440-p" @default.
• W4293073886 hasPublicationYear "2022" @default.
• W4293073886 type Work @default.
• W4293073886 citedByCount "1" @default.
• W4293073886 countsByYear W42930738862023 @default.
• W4293073886 crossrefType "journal-article" @default.
• W4293073886 hasAuthorship W4293073886A5020385332 @default.
• W4293073886 hasAuthorship W4293073886A5025293866 @default.
• W4293073886 hasAuthorship W4293073886A5055924693 @default.
• W4293073886 hasAuthorship W4293073886A5073693745 @default.
• W4293073886 hasAuthorship W4293073886A5082171339 @default.
• W4293073886 hasAuthorship W4293073886A5090069649 @default.
• W4293073886 hasConcept C126322002 @default.
• W4293073886 hasConcept C134018914 @default.
• W4293073886 hasConcept C168563851 @default.
• W4293073886 hasConcept C203092338 @default.
• W4293073886 hasConcept C2777180221 @default.
• W4293073886 hasConcept C2780586474 @default.
• W4293073886 hasConcept C2780780548 @default.
• W4293073886 hasConcept C2781308992 @default.
• W4293073886 hasConcept C511355011 @default.
• W4293073886 hasConcept C544821477 @default.
• W4293073886 hasConcept C555293320 @default.
• W4293073886 hasConcept C71924100 @default.
• W4293073886 hasConcept C90924648 @default.
• W4293073886 hasConceptScore W4293073886C126322002 @default.
• W4293073886 hasConceptScore W4293073886C134018914 @default.
• W4293073886 hasConceptScore W4293073886C168563851 @default.
• W4293073886 hasConceptScore W4293073886C203092338 @default.
• W4293073886 hasConceptScore W4293073886C2777180221 @default.
• W4293073886 hasConceptScore W4293073886C2780586474 @default.
• W4293073886 hasConceptScore W4293073886C2780780548 @default.
• W4293073886 hasConceptScore W4293073886C2781308992 @default.
• W4293073886 hasConceptScore W4293073886C511355011 @default.
• W4293073886 hasConceptScore W4293073886C544821477 @default.
• W4293073886 hasConceptScore W4293073886C555293320 @default.
• W4293073886 hasConceptScore W4293073886C71924100 @default.
• W4293073886 hasConceptScore W4293073886C90924648 @default.
• W4293073886 hasIssue "Supplement_1" @default.
• W4293073886 hasLocation W42930738861 @default.
• W4293073886 hasOpenAccess W4293073886 @default.
• W4293073886 hasPrimaryLocation W42930738861 @default.
• W4293073886 hasRelatedWork W1887950352 @default.
• W4293073886 hasRelatedWork W199595286 @default.
• W4293073886 hasRelatedWork W2060979843 @default.
• W4293073886 hasRelatedWork W2085240166 @default.
• W4293073886 hasRelatedWork W2126334399 @default.
• W4293073886 hasRelatedWork W2170150042 @default.
• W4293073886 hasRelatedWork W2334466739 @default.
• W4293073886 hasRelatedWork W4293073886 @default.
• W4293073886 hasRelatedWork W4310960180 @default.
• W4293073886 hasRelatedWork W4319657262 @default.
• W4293073886 hasVolume "71" @default.
• W4293073886 isParatext "false" @default.
• W4293073886 isRetracted "false" @default.
• W4293073886 workType "article" @default.